Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Eur J Pharm Biopharm. 2021 Mar 24;163:72–101. doi: 10.1016/j.ejpb.2021.03.010

Fig. 4.

Fig. 4.

a) Schematic showing the fabrication of the anti-CD3e f(ab′)2 fragments attached poly(β-amino ester) nanoparticles. b) Schematic showing the conjugation of PIGF-2 peptide to IgG antibody for improving the binding to ECM proteins. Adopted with permission from reference [107] (a) and [115] (b)